NCT06558877 Effect of a Pharmacist-led Multifaceted Intervention on Treatment Outcomes in Hypertensive Patients
| NCT ID | NCT06558877 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Xijing Hospital |
| Condition | Hypertension |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,200 participants |
| Start Date | 2025-06-20 |
| Primary Completion | 2027-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,200 participants in total. It began in 2025-06-20 with a primary completion date of 2027-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of this cluster randomized controlled trial is to evaluate the effectiveness of a pharmacist-led multifaceted intensive blood pressure intervention on poorly controlled hypertensive patients in phase 1 (1 month, 3 months, 6 months, 12 months) and phase 2 (24 months) post randomization.
Eligibility Criteria
Inclusion Criteria (subjects must meet all of the following criteria to be included): * 1\) age 18-80 years; * 2\) patients with hypertension (diagnostic criteria: defined as systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg according to the "Guidelines for the prevention and treatment of hypertension in China in 2023", based on the blood pressure measurement of three times on different days), who are currently taking anti-hypertensive medication and are judged by the research physician to have poor blood pressure control; * 3\) able to use smartphones and WeChat proficiently, and can communicate and upload pictures proficiently; * 4\) able to take care of yourself and communicate normally, and willing to cooperate with the research physician to complete the study and follow-up; * 5\) permanent residents of the city where the center is located; * 6\) voluntarily participate and sign the informed consent form Exclusion Criteria(subjects will be excluded if they meet any of the following criteria): * 1\) patients with advanced disease (such as patients undergoing dialysis or liver failure), or with a life expectancy of less than 2 years as determined by the research physician; * 2\) combined with psychiatric disease, cognitive impairment, communication disorder, or inability to cooperate with the researchers; * 3\) combined with cerebrovascular disease, stroke, severe liver and kidney dysfunction, severe heart failure, cancer and history of organ transplantation, etc.; * 4\) patients who are pregnant, breastfeeding, or planning to conceive in the next 2 years.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06558877 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06558877 currently recruiting?
Yes, NCT06558877 is actively recruiting participants. Contact the research team at dongqq@fmmu.edu.cn for enrollment information.
Where is the NCT06558877 trial being conducted?
This trial is being conducted at Xi'an, China.
Who is sponsoring the NCT06558877 clinical trial?
NCT06558877 is sponsored by Xijing Hospital. The trial plans to enroll 1,200 participants.